Breast Cancer | Meet The Professor: Optimizing the Management of HER2-Positive Breast Cancer — Part 3
Featuring perspectives from Dr Lisa Carey, including the following topics: Introduction: Journal Club with Lisa A Carey, MD, ScM (0:00) Case: A woman in her late 70s presents with triple-positive breast cancer and a suspicious mass in the liver — Zanetta S Lamar, MD (8:51) Case: A woman in her mid 40s with ER/PR-negative, HER2-positive metastatic breast cancer with a complete response to paclitaxel/trastuzumab/pertuzumab develops multiple brain metastases 3 months later — Niyati A Nathwani, MD (19:01) Case: A woman in her mid 30s with triple-positive breast cancer develops brain metastases 5 years after primary neoadjuvant treatment — Rahul Gosain, MD (22:23) Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer experiences progressive disease after abemaciclib/ovarian function suppression and an aromatase inhibitor — Laila Agrawal, MD (28:22) Case: A woman in her early 60s with ER/PR-positive, HER2-negative localized breast cancer develops triple-positive metastatic breast cancer — Mamta Choksi, MD (41:16) Case: A woman in her early 50s with 1.2-cm triple-positive breast cancer who underwent mastectomy (surgical specimen HER2-negative) and adjuvant paclitaxel/trastuzumab now presents with HER2-negative localized recurrence — Namrata I Peswani, MD (43:37) Faculty Survey (47:53) Ongoing Trials; Reported Data; Review Articles (55:01) CME information and select publications